Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • DKFZ Publication Database  (3)
  • COLON-CANCER  (2)
  • interaction  (2)
  • Thermal comfort
Collection
Keywords
  • 1
    Keywords: RECEPTOR ; CANCER ; BLOOD ; POPULATION ; RISK ; GENE ; GENES ; BIOMARKERS ; colon ; ASSOCIATION ; polymorphism ; POLYMORPHISMS ; VARIANTS ; ADENOMAS ; HEALTH ; colorectal cancer ; REDUCED RISK ; COLORECTAL-CANCER ; GENOTYPES ; COLON-CANCER ; POPULATIONS ; UNITED-STATES ; case-control studies ; CALCIUM ; nutrition ; RECTAL-CANCER ; SERUM ; case control study ; case-control study ; REGRESSION ; colon cancer ; VARIANT ; interaction ; LEVEL ; biomarker ; EPIDEMIOLOGIC EVIDENCE ; GENOTYPE ; USA ; prospective ; rectal cancer ; cancer research ; colorectal ; vitamin D ; VITAMIN-D ; LOGISTIC-REGRESSION ; D METABOLITES ; vitamin D receptor ; 25-HYDROXYVITAMIN-D ; RECTAL CANCERS ; Genetic ; VITAMIN ; CONFIDENCE ; CRC ; Logistic regression ; D-RECEPTOR ; DIETARY CALCIUM
    Abstract: Increased levels of vitamin D and calcium may play a protective role in colorectal cancer (CRC) risk. It has been suggested that these effects may be mediated by genetic variants of the vitamin D receptor (VDR) and the calcium sensing receptor (CASR). However, current epidemiologic evidence from European populations for a role of these genes in CRC risk is scarce. In addition, it is not clear whether these genes may modulate CRC risk independently or by interaction with blood vitamin D concentration wild-type bb, the BB genotype of the VDR BsmI polymorphism was associated with a reduced risk of CRC [RR, 0.76; 95% confidence interval (CI), 0.59-0.98). The association was observed for colon cancer (RR, 0.69; 95% CI, 0.45-0.95) but not rectal cancer (RR, 0.97; 95% CI, 0.62-1.49). The Fok1 and CASR genotypes were not associated with CRC risk in thisand level of dietary calcium intake. A case-control study was conducted nested within the European Prospective Investigation into Cancer and Nutrition. CRC cases (1,248) were identified and matched to 1,248 control subjects. Genotyping for the VDR (BsmI: rs1544410; Fok1: rs2228570) and CASR (rs1801725) genes was done by Taqman, and serum vitamin D (25OHD) concentrations were measured. Conditional logistic regression was used to estimate the incidence rate ratio (RR). Compared with the study. No interactions were noted for any of the polymorphisms with serum 25OHD concentration or level of dietary calcium. These results confirm a role for the BsmI polymorphism of the VDR gene in CRC risk, independent of serum 25OHD concentration and dietary calcium intake. (Cancer Epidemiol Biomarkers Prev 2009;18(9):2485-91)
    Type of Publication: Journal article published
    PubMed ID: 19706842
    Signatur Availability
    BibTip Others were also interested in ...
  • 2
    Keywords: CANCER ; COHORT ; POPULATION ; RISK ; RISK-FACTORS ; ASSOCIATION ; OBESITY ; COLON-CANCER ; nutrition ; IGF-I ; SERUM-LEVELS ; VITAMIN-D STATUS ; CALCIUM-SENSING RECEPTOR ; PRIMARY HYPERPARATHYROIDISM ; PTH/PTHRP RECEPTOR
    Abstract: Background: Parathyroid hormone (PTH) has been proposed to play a promoting role in carcinogenesis. However, no epidemiologic studies have yet directly investigated its role in colorectal cancer (CRC). Methods: A case-control study nested within the European Prospective Investigation into Cancer and Nutrition cohort was conducted with 1,214 incident, sporadic CRC cases matched to 1,214 controls. Circulating prediagnostic PTH and 25-hydroxy vitamin D [25(OH) D] concentrations were measured by enzyme-linked immunosorbent assays. Detailed dietary and lifestyle questionnaire data were collected at baseline. Multivariable conditional logistic regression was used to estimate the incidence rate ratio (RR) with 95% confidence intervals (95% CI) for the association between circulating PTH and CRC risk. Results: In multivariate analyses [including adjustment for 25(OH) D concentration] with a priori defined cutoff points, high levels of serum PTH (〉= 65 ng/L) compared with medium PTH levels of 30-65 ng/L were associated with increased CRC risk (RR = 1.41,95% CI: 1.03-1.93). In analyses by sex, the CRC risk was 1.77 (95% CI: 1.14-2.75) and 1.15 (95% CI: 0.73-1.84) in men and women, respectively (P-heterogeneity = 0.01). In subgroup analyses by anatomical subsite, the risk for colon cancer was RR = 1.56, 95% CI: 1.03-2.34, and for rectal cancer RR = 1.20, 95% CI: 0.72-2.01 (P-heterogeneity = 0.21). Effect modification by various risk factors was examined. Conclusions: The results of this study suggest that high serum PTH levels may be associated with incident, sporadic CRC in Western European populations, and in particular among men. Impact: To our knowledge, this is the first study on PTH and CRC. The role of PTH in carcinogenesis needs to be further investigated.
    Type of Publication: Journal article published
    PubMed ID: 21378267
    Signatur Availability
    BibTip Others were also interested in ...
  • 3
    Keywords: CELLS ; AGENTS ; human ; THERAPY ; CLASSIFICATION ; DIAGNOSIS ; SYSTEM ; TOOL ; DIFFERENTIATION ; MOLECULES ; TISSUE ; ANTIGEN ; ANTIGENS ; BIOLOGY ; MOLECULE ; antibodies ; antibody ; GLYCOPROTEIN ; SURFACE ; STRATEGIES ; pathology ; NOMENCLATURE ; AGENT ; RE ; interaction ; IMMUNE-SYSTEM ; cell differentiation
    Abstract: The immune system works through leukocytes interacting with each other, with other cells, with tissue matrices, with infectious agents, and with other antigens. These interactions are mediated by cell-surface glycoproteins and glycolipids. Antibodies against these leukocyte molecules have provided powerful tools for analysis of their structure, function, and distribution. Antibodies have been used widely in hematology, immunology, and pathology, and in research, diagnosis, and therapy. The associated CD nomenclature is commonly used when referring to leukocyte surface molecules and antibodies against them. It provides an essential classification for diagnostic and therapeutic purposes. The most recent (8th) Workshop and Conference on Human Leukocyte Differentiation Antigens (HLDA), held in Adelaide, Australia, in December 2004, allocated 95 new CD designations and made radical changes to its aims and future operational strategy in order to maintain its relevance to modern human biology and clinical practice
    Type of Publication: Journal article published
    PubMed ID: 16020511
    Signatur Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...